About the role
<div class="content-intro"><p><strong>About General Atlantic</strong></p> <p>General Atlantic is a leading global investor with more than four and a half decades of experience providing capital and strategic support for over 830 companies throughout its history. Established in 1980, General Atlantic continues to be a dedicated partner to visionary founders and investors seeking to build dynamic businesses and create long term value. Guided by the conviction that entrepreneurs can be incredible agents of transformational change, the firm combines a collaborative global approach, sector specific expertise, a long-term investment horizon, and a deep understanding of growth drivers to partner with and scale innovative businesses around the world. The firm leverages its patient capital, operational expertise, and global platform to support a diversified investment platform spanning Growth Equity, Credit, Climate, and Sustainable Infrastructure strategies. General Atlantic manages approximately $126 billion in assets under management, inclusive of all strategies, as of December 31, 2025, with more than 900 professionals in 20 countries across five regions. For more information on General Atlantic, please visit: <a href="http://www.generalatlantic.com" target="_blank" data-sk="tooltip_parent">www.generalatlantic.com</a>.</p></div><p><span style="text-decoration: underline;">General Atlantic Life Sciences Practice</span></p> <p>The GA Life Sciences practice provides capital and strategic support for development stage biopharma companies, with an established track record across public and private investments. The Life Sciences team focuses on novel therapies that provide substantial patient benefit and have the potential to redefine standards of care. GA’s differentiated approach to life sciences is characterized by highly thematic investing, scaling significant capital into companies as they advance through clinical development and commercialization, and partnering with management teams to generate value. Investments include Akero Therapeutics (acquired by Novo Nordisk), Karuna Therapeutics (acquired by BMS), Cincor Pharma (acquired by AstraZeneca), and Centessa Pharmaceuticals (potential acquisition by Eli Lilly).</p> <p><span style="text-decoration: underline;">Position Summary</span></p> <p>General Atlantic is seeking a Life Sciences investor to join our New York‑based investment team. This role will have exposure to all parts of the investment process, including evaluating new investment opportunities and investment themes in biopharma and life science companies, conducting technical diligence, supporting deal execution, and working with portfolio companies. The ideal candidate will have a scientific background (MD or PhD) and at least two years of relevant industry e